Tagrisso-Savolitinib Win in MET-Driven NSCLC Adds Positive Data Point, but AZN Valuation Still Full

What happened

AstraZeneca announced positive Phase III SAFFRON results showing Tagrisso plus savolitinib reduced risk of progression or death by 45% and death by 32% versus chemotherapy in EGFR-mutated NSCLC patients with MET overexpression/amplification who had progressed on Tagrisso. This addresses a key resistance mechanism and could extend Tagrisso's lifecycle in a biomarker-defined subset, but the press release lacks detailed efficacy and safety data, so clinical significance beyond headline numbers remains to be seen. The result fits the company's 'catalyst-rich' narrative but does not erase the mixed pipeline record disclosed earlier, including the LATIFY OS miss and DUO-O no-filing decision. From the master report, AZN trades at $188.1 with P/E 28.1x and EV/EBITDA 15.9x, leaving little room for setbacks, and the WAIT rating reflects need for confirmatory approvals outweighing setbacks and legal/investigation clarity. While this positive trial data could support future regulatory filing and commercial expansion, it is insufficient alone to shift valuation or rating without further evidence of broad pipeline productivity.

Implication

Investors should view this as a modest positive for the Oncology franchise, potentially supporting future label expansion for Tagrisso in a biomarker-defined subgroup, but not a thesis-changing event given valuation already prices durable pipeline delivery. The stock may see a short-term boost on the headline, but at $188.1 it is above the attractive entry level of $170 and below the trim level of $215, leaving limited margin of safety. Key risks remain: legal/investigation overhang, mixed R&D productivity, and need for more approvals to outnumber setbacks. If the stock rallies toward $215, trimming makes sense; if it pulls back to $170, entry improves. Monitor subsequent filings for detailed data, regulatory interactions, and any impairment signals; do not underwrite multiple expansion solely on this single trial result.

Thesis delta

The prior WAIT thesis is unchanged: valuation remains full and requires broader pipeline delivery. The SAFFRON result moderately strengthens the bull case by demonstrating a viable combination in a resistant population, but it does not resolve the mixed R&D productivity or legal/investigation uncertainties highlighted in the master report. Consequently, no rating change is warranted, though the probability of near-term Oncology impairment decreases slightly.